Hansen Medical Boosts IP Portfolio - Analyst Blog
25 8월 2012 - 1:07AM
Zacks
Hansen Medical
(HNSN), a global developer and manufacturer of intravascular
robotics, recently announced the expansion of its intellectual
property portfolio on the back of 30 additional patents in the U.S.
since January 2011. The company also shares the rights to more than
250 issued U.S. patents associated with medical robotics via
licensing with third parties.
Many of these additional patents
bestow further coverage and exclusionary rights for Hansen
Medical’s Magellan Robotic System. It received the 510(k) clearance
from the U.S. Food and Drug Association (FDA) for the system on
June 4, 2012. Management believes that Magellan Robotic Systems has
a latent quality, in that it can be a major growth driver for the
company.
The Magellan Robotic System has the
potential to revolutionize peripheral vascular intervention because
of improved lesion access, precise control over distal tip, solid
catheter stability and procedural efficiency. Hansen Medical has
already initiated a commercial launch for the system in the
European Union, where it received the CE Mark in July 2011.
Additionally, the system has been approved in Australia, while it
is pending approval in Canada.
Certain patents also improve the
coverage for Hansen Medical’s Sensei X Robotic Catheter System.
According to the company, Magellan Robotic Systems along with
Sensei X Robotic Catheter System is expected to catalyze its
top-line.
In an industry where companies
constantly undergo fluid innovation and technological advancement,
patent protection is an increasingly urgent issue. Hansen Medical
continues to enhance its intellectual property portfolio, helped by
stimulating research and innovation.
The robotic systems have a unique
selling proposition for hospitals as it offers quality patient care
while improving organizational efficiency. However, unsuccessful
commercialization and a low adoption rate for the robotic systems
are matters of concern. In the end, the financial results of Hansen
Medical depend on the operating efficiency and successful
commercialization of its robotic systems.
The company faces a tough
competitive landscape with large cap market players like
Boston Scientific Corporation (BSX),
Johnson and Johnson (JNJ) and others like
Stereotaxis Inc. (STXS) in the U.S. But the 30
additional U.S. patents will keep direct competition at bay.
Hansen Medical holds a Zacks #3
Rank, which translates into a short-term Hold rating.
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
HANSEN MEDICAL (HNSN): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
STEREOTAXIS INC (STXS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024